A publicly traded biotech giant based in South Korea is turning to blockchain to allow it to share genetic data without risk of hacking or infringement of patients' privacy.
Macrogen, a DNA sequencing service provider with headquarters in Seoul, said in a press release on Monday that it is working with Big Data firm Bigster to develop a blockchain network for the distribution of genomic information, which is slated for completion by June 2019.
In the medical field, according to the release, genomic data is used for customized patient diagnosis and treatment, while the pharmaceutical industry can use it for the development of new drugs and therapeutic agents.
Yet, despite the high utilization value of DNA data within healthcare, it is not widely shared due to the sensitive nature of the information to patients and the risk of privacy breaches.
Yang Kap-seok, CEO of Macrogen, commented in the release:
To that end, the firms plan a system based on a consortium blockchain model that will only allow invited parties – such as pharmaceutical firms, research institutes, hospitals and genetic analysis startups – to run as nodes on the decentralized network, limiting who can access the data.
Macrogen is not the only technology giant looking to apply blockchain tech within the genomics industry.
As far back as 2014, an Israeli startup called DNA.Bits announced plans to store genetic and medical record data using blockchain technology.
And, as previously reported by CoinDesk, a patent application filed by Intel indicated that the hardware firm is exploring ways to take advantage of the energy generated during cryptocurrency mining to sequence DNA.
DNA sequence image via Shutterstock
The leader in news and information on cryptocurrency, digital assets and the future of money, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups. As part of their compensation, certain CoinDesk employees, including editorial employees, may receive exposure to DCG equity in the form of stock appreciation rights, which vest over a multi-year period. CoinDesk journalists are not allowed to purchase stock outright in DCG.
Learn more about Consensus 2023, CoinDesk’s longest-running and most influential event that brings together all sides of crypto, blockchain and Web3. Head to consensus.coindesk.com to register and buy your pass now.